NVS - Gilead Doubles Down On Its NASH Pipeline With $1.5B Deal
Recently, Gilead Sciences (GILD) announced that it had entered into a strategic collaboration with a company by the name of Scholar Rock Holding Corporation (SRRK). The reason for this deal is so that Gilead could gets its hands on another type of technology to target the ever growing NASH fibrosis space. This is another huge commitment for Gilead, because it has spent countless of cash looking for the next blockbuster NASH drug.
Massive Partnership Deal
The deal centers around a pre-clinical program that is using inhibitors of Transforming growth factor Beta